ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Granulocyte Colony-Stimulating Factor

Also written as “G-CSF plus plerixafor”, “G-CSF Plus Plerixafor” and “G-CSF”.

Its studies are mostly in Multiple Myeloma · Lymphoma, Non-Hodgkin · Sarcoma · Infertility, Female · Hot Flashes, led by 6 companies.

Drug pageGranulocyte Colony-Stimulating Factor: every studyMany companies study it; this page follows only the 16 they lead. All 179 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 9, 202116 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi110 open or runningphase 4since Oct 9, 2021Feb 11, 2005none ahead
Axaron Bioscienceits history only10 open or runningphase 2since Aug 18, 2005Aug 18, 2005none ahead
CSLits history only10 open or runningphase 1since May 31, 2019May 31, 2019none ahead
MenoGeniXits history only10 open or runningphase 1since Jul 30, 2018Jul 30, 2018none ahead
Newlife Fertility Centreits history only11 open or runningphase 4since Dec 8, 2023Dec 8, 2023none ahead
Terumoits history only10 open or runningno phasesince Sep 23, 2014Sep 23, 2014none ahead

Also a collaborator on its studies: AnorMED.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 11, 2005First studies: 2 phase 3 studiesFirst studyNCT00103662, NCT00103610
  2. May 4, 20063 phase 2 studies in Lymphoma, Non-HodgkinNCT00322842, NCT00322491, NCT00322387
  3. Nov 2, 20064 phase 2 studiesNCT00396331, NCT00396266, NCT00396201 and 1 more
  4. Mar 7, 2007Phase 2 study in Lymphoma, Non-HodgkinNCT00444912 · 30 enrolled · United States
  5. Oct 9, 2021Phase 4 study in Autologous Haematopoietic Stem Cell TransplantNCT05087212 · 53 enrolled · China
  6. Feb 29, 2024Named granulocyte colony-stimulating factorINNProposed as its International Nonproprietary Name in WHO's List 130

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05087212Autologous Haematopoietic Stem Cell Transplant · China4CompletedDec 6, 202253
NCT00444912Lymphoma, Non-Hodgkin · United States2CompletedJun 200930
NCT00396331Multiple Myeloma · United States2CompletedDec 2009100
NCT00396266Multiple Myeloma · Canada2CompletedDec 200722
NCT00396201Hodgkin Disease · United States2CompletedOct 200622
NCT00395967Multiple Myeloma · United States2TerminatedJul 20055
NCT00322842Lymphoma, Non-Hodgkin · Germany2CompletedFeb 200735
NCT00322491Lymphoma, Non-Hodgkin · United States2CompletedJun 200649
NCT00322387Lymphoma, Non-Hodgkin · United States2CompletedJul 200640
NCT00103662Multiple Myeloma · United States, Canada, Germany3CompletedOct 2006302
NCT00103610Lymphoma, Non-Hodgkin · United States, Canada3CompletedJul 2006298

How it is read

Names in the registry

  • “G-CSF plus plerixafor”, 4 entries
  • “G-CSF Plus Plerixafor”, 4 entries
  • “G-CSF”, 3 entries
  • “Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous”, 2 entries
  • “Granulocyte colony-stimulating factor plus plerixafor”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.